Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10639549 | 0.88 | TP53 (0.40) | NPSR1ALDH1A1 | |
| SCHEMBL10636994 | 0.87 | FPR1 (0.42) | — | |
| SCHEMBL10642654 | 0.87 | SMN1; SMN2 (0.47) | NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10637719 | 0.87 | FPR1 (0.42) | ALDH1A1LMNAKDM1A | |
| SCHEMBL10638158 | 0.87 | NPSR1 (0.42) | NPSR1ALDH1A1LMNASMN1; SMN2KDM1A | |
| SCHEMBL10642101 | 0.86 | NPSR1 (0.40) | NPSR1ALDH1A1LMNA | |
| SCHEMBL5481415 | 0.85 | NPSR1 (0.45) | NPSR1ALDH1A1LMNAKDM1A | |
| SCHEMBL10639220 | 0.84 | GPBAR1 (0.40) | ALDH1A1MAPK1KDM1A | |
| SCHEMBL10642483 | 0.84 | GPBAR1 (0.42) | NPSR1ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10642036 | 0.82 | KMT2A (0.41) | NPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0164853-B1 | (SUBSTITUTED-PHENYL)-5-OXO-2-PYRROLIDINEPROPANOIC ACIDS, A PROCESS FOR PRODUCING THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1988-07-06 | — | — | EP | claimed |
| US-4584313-A | TREATING SENILITY | WARNER-LAMBERT COMPANY (US) | 1986-04-22 | — | — | US | claimed |
| EP-0164853-A1 | (substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids, a process for producing the compounds and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-12-18 | — | — | EP | claimed |
| US-20070270436-A1 | NOVEL AMINO- AND IMINO-ALKYLPIPERAZINES | RECORDATI IRELAND LIMITED (IE) | 2007-11-22 | — | — | US | disclosed |
| EP-0164852-B1 | 1-(SUBSTITUTED-ARYL)-DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H-)DIONES, A PROCESS FOR PRODUCING THE COMPOUNDS AND A PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0164853-B1 | (SUBSTITUTED-PHENYL)-5-OXO-2-PYRROLIDINEPROPANOIC ACIDS, A PROCESS FOR PRODUCING THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4584313-A | TREATING SENILITY | WARNER-LAMBERT COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0164852-A1 | 1-(Substituted-aryl)-Dihydro-1H-pyrrolizine-3,5-(2H,6H-)diones, a process for producing the compounds and a pharmaceutical composition comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| EP-0164853-A1 | (substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids, a process for producing the compounds and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4548947-A | 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia | WARNER-LAMBERT COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270436-A1 | NOVEL AMINO- AND IMINO-ALKYLPIPERAZINES | HTR5A, HTR1A, HTR2C | NPSR1 74/4885ALDH1A1 962/4885LMNA 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.